Suramin affects metalloproteinase-9 activity and increases beta-dystroglycan levels in the diaphragm of the dystrophin-deficient mdx MOUSE

Muscle and Nerve

Volumn 46, Issue 5, 2012, Pages 810-813

  Taniguti, Ana Paula Tiemi ^a   Matsumura, Cíntia Yuri ^a   Rodrigues Simioni, Léa ^a   Neto, Humberto Santo ^a   Marques, Maria Julia ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Beta dystroglycan; DMD; mdx; Metalloproteinases; Suramin

Indexed keywords

BETA DYSTROGLYCAN; GELATINASE A; GELATINASE B; SURAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CONTROLLED STUDY; DIAPHRAGM; ENZYME ACTIVITY; FATIGUE; FEMALE; IN VITRO STUDY; MALE; MOUSE; MUSCLE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; DIAPHRAGM; DYSTROGLYCANS; DYSTROPHIN; ENZYME ACTIVATION; FEMALE; FIBROSIS; MALE; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE FATIGUE; MUSCULAR DYSTROPHY, DUCHENNE; SURAMIN; UP-REGULATION;

EID: 84867383138     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23468     Document Type: Article

References (39)

1. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-928.
2. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991; 352: 536-538.
3. Engel AG, Yamamoto M, Fischbeck KH. Muscular dystrophies. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: McGraw-Hill; 1994. p 1133-1187.
4. Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, et al. Expression of transforming growth factor-beta1 in dystrophic patient muscles correlates with fibrosis. J Clin Invest 1995; 96: 1137-1144.
5. Gosselin LE, Williams JE, Deering M, Brazeau D, Koury S, Martinez DA. Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. Muscle Nerve 2004; 30: 645-653.
6. Zanotti S, Saredi S, Ruggieri A, Fabbri M, Blasevich F, Romaggi S, et al. Altered extracellular matrix transcript expression and protein modulation in primary Duchenne muscular dystrophy myotubes. Matrix Biol 2007; 26: 615-624.
7. Roberts AB, Heine UI, Flanders KC, Sporn MB. Transforming growth factor-beta. Major role in regulation of extracellular matrix. Ann N Y Acad Sci 1990; 580: 225-232.
8. Serrano AL, Munoz-Canoves P. Regulation and dysregulation of fibrosis in skeletal muscle. Exp Cell Res 2010; 316: 3050-3058.
9. Carmeli E, Moas M, Reznick AZ, Coleman R. Matrix metalloproteinases and skeletal muscle: a brief review. Muscle Nerve 2004; 29: 191-197.
10. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
11. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol 2001;13: 534-540.
12. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodeling. Nat Rev Mol Cell Biol 2007; 8: 221-233.
13. Yamada H, Saito F, Fukuta-Ohi H, Zhong D, Hase A, Arai K, et al. Processing of beta-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. Hum Mol Genet 2001; 10: 1563-1569.
14. Matsumura K, Zhong D, Saito F, Arai K, Adachi K, Kawai H et al. Proteolysis of beta-dystroglycan in muscular diseases. Neuromuscul Disord 2005; 15: 336-341.
15. Zhong D, Saito F, Saito Y, Nakamura A, Shimizu T, Matsumura K. Characterization of the protease activity that cleaves the extracellular domain of beta-dystroglycan. Biochem Biophys Res Commun 2006; 345: 867-871.
16. Michaluk P, Kolodziej L, Mioduszewska B, Wilczynski GM, Dzwonek J, Jaworski J, et al. Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J Biol Chem 2007; 282: 16036-16041.
17. Taniguti APT, Pertille A, Matsumura CY, Santo Neto H, Marques MJ. Prevention of muscle fibrosis by suramin, a TGF-beta1 blocker. Muscle Nerve 2010; 43: 82-87.
18. Lossos IS, Izbicki G, Or R, Goldstein RH, Breuer R. The effect of suramin on bleomycin-induced lung injury. Life Sci 2000; 67: 2873-2881.
19. Bulbring E. Observation on the isolated phrenic nerve diaphragm preparation of rat. Br J Pharmacol 1946; 1: 38-61.
20. Soares AM, Oshima-Franco Y, Vieira CA, Leite GB, Fletcher JE, Jiang MS, et al. Mn(2+) ions reduce the enzymatic and pharmacological activities of bothropstoxin-I, a myotoxic Lys49 phospholipase A(2) homologue from Bothrops jararacussu snake venom. Int J Biochem Cell Biol 2002; 34: 668-677.
21. Rodrigues-Simioni L, Floriano RS, Rostelato-Ferreira S, Sousa NC, Marangoni S, Ponce-Soto LA, et al. Presynaptic action of Bothriopsis bilineata smargadina (forest viper) venom in vitro. Toxicon 2011; 58: 140-145.
22. Kherif S, Lafuma C, Dehaupas M, Lachkar S, Fournier JG, Verdiere-Sahuque M, etal. Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev Biol 1999; 205: 158-170.
23. Faulkner JA, Ng R, Davis CS, Li S, Chamberlain JS. Diaphragm muscle strip preparation for evaluation of gene therapies in mdx mice. Clin Exp Pharmacol Physiol 2008; 35: 725-729.
24. Personius KE, Sawyer RP. Variability and failure of neurotransmission in the diaphragm of mdx mice. Neuromuscul Disord 2006; 16: 168-177.
25. Burdi R, Rolland JF, Fraysse B, Litvinova K, Cozzoli A, Giannuzzi V, et al. Multiple pathological events in exercised dystrophic mdx are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests. J Appl Physiol 2009; 106: 1311-1324.
26. Von Moers A, Zwirner A, Reinhold A, Bruckmann O, Van Landeghem F, Stoltenburg-Didinger G, et al. Increased mRNA expression of tissue inhibitors of metalloproteinase-1 and -2 in Duchenne muscular dystrophy. Acta Neuropathol 2005; 109: 285-293.
27. Fukushima K, Nakamura A, Ueda H, Yuasa K, Yoshida K, Takeda S, et al. Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ). BMC Musculoskelet Disord 2007; 8: 54-64.
28. Hnia K, Hugon G, Rivier F, Masmoudi A, Mercier J, Mornet D. Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient mdx mice. Am J Pathol 2007; 170: 633-643.
29. Bani C, Lagrota-Candido J, Pinheiro DF, Leite PEC, Salimena MC, Henriques-Pons A, etal. Pattern of metalloprotease activity and myofiber regeneration in skeletal muscles of mdx mice. Muscle Nerve 2008; 37: 583-592.
30. Li H, Mittal A, Makonchuk DY, Bhatnagar S, Kumar A. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum Mol Genet 2009; 18: 2584-2598.
31. Gu BJ, Wiley JS. Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood 2006; 107: 4946-4953.
32. Hnia K, Gayraud J, Hugon G, Ramonatxo M, De La Porte S, Matecki S, et al. L-arginine decreases inflammation and modulates the nuclear factor-κB/matrix metalloproteinase cascade in mdx muscle fibers. Am J Pathol 2008; 172: 1509-1519.
33. Hsieh HL, Wang HH, Wu WB, Chu PJ, Yang CM. Transforming growth factor-beta1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK- NF-κB pathways. J Neuroinflammation 2010; 7: 88-104.
34. Grounds MD, Radley HG, Gebski BL, Bogoyevitch MA, Shavlakadze T. Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle. Clin Exp Pharmacol Physiol 2008; 35: 846-851.
35. Iwata Y, Katanosaka Y, Hisamitsu T, Wakabayashi S. Enhanced Na+/H+ exchange activity contributes to the pathogenesis of muscular dystrophy via involvement of P2 receptors. Am J Pathol 2007; 171: 1576-1587.
36. McGeary RP, Bennett AJ, Tran QB, Cosgrove KL, Ross BP. Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem 2008; 8: 1384-1394.
37. Koppanati BM, Li J, Reay DP, Wang B, Daood M, Zheng H, et al. Improvement of the mdx mouse dystrophic phenotype by systemic in utero AAV8 delivery of a minidystrophin gene. Gene Ther 2010; 17: 1355-1362.
38. Sanderson L, Khan A, Thomas S. Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice. Antimicrob Agents Chemother 2007; 51: 3136-3146.
39. Kumar A, Bhatnagar S, Kumar A. Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. Am J Pathol 2010; 177: 248-260.